Estudio de utilización de linezolid en el Hospital Central de la Defensa «Gómez Ulla»

  1. M. Fernández-García 1
  2. A. Carvajal-Fernández 2
  3. R. M. Aparicio-Hernández 3
  4. A. García-Luque 4
  1. 1 Teniente médico. Agrupación Base Aérea de Zaragoza. Zaragoza. España.
  2. 2 Teniente médico. Agrupación Base Aérea de Torrejón. Madrid. España.
  3. 3 Médico adjunto del Servicio Farmacología Clínica. Hospital Central de la Defensa. Madrid. España.
  4. 4 Teniente coronel médico. Servicio Farmacología Clínica. Hospital Central de la Defensa. Madrid. España.
Erakutsi afiliazioak +
Aldizkaria:
Sanidad militar: revista de sanidad de las Fuerzas Armadas de España

ISSN: 1887-8571

Argitalpen urtea: 2022

Alea: 78

Zenbakia: 2

Orrialdeak: 70-73

Mota: Artikulua

DIALNET GOOGLE SCHOLAR lock_openSarbide irekia editor

Beste argitalpen batzuk: Sanidad militar: revista de sanidad de las Fuerzas Armadas de España

Laburpena

Linezolid is an antimicrobial from the group of oxazolidinones, developed in the 1990s, being the first marketed in its group in the early 2000s. It is indicated, according to the data sheet, in the treatment of nosocomial pneumonia. and community-acquired pneumonia, when known or suspected to be caused by gram positive bacteria, and in the treatment of complicated skin and soft tissue infections with certain gram positive organisms. Due to its good pharmacokinetics, profitability and aforementioned indications, it has gained special importance both in hospital and outpatient settings. Subjects and methods: A retrospective prescription-indication drug use study was carried out at the Central Defense Hospital (HCD) «Gómez Ulla», during the month of September 2019, with the objective of knowing the pattern of use of linezolid (indications, adequacy or not to the data sheet, dosage regimen, route of administration used, suspected adverse drug reactions, sociodemographic and clinical characteristics of the patients). The type of test was non-probabilistic consecutive. A descriptive statistical analysis was performed using the SPSS 25.0 computer program. Results: A total of 28 patients received at least one dose of linezolid during the month of September 2019. IPPB was the most prevalent indication (53.5%) (15/28) followed by pneumonia (28.5%) (8/28). It was not adapted in 5 cases (17.8%) (5/28) to the indications of the data sheet: Complicated Urinary Tract Infection (3/5), Complicated Intra-abdominal Infection (1/5) and febrile syndrome without source (1/5). The infection was considered nosocomial in 32% (9/28) of the cases, 57% (16/28) of the sample had plasma creatinine ≥ 1.2mg/dl at the start of treatment. The dose used was 600 mg/12 h in all patients, with a median duration of treatment of 9.5 days. The intravenous route of administration was used in 71% of the cases (20 cases), among these cases in 10% of the patients (2/20) sequential therapy was not performed despite the fact that there was no contraindication for it. No adverse drug reactions (ADRs) were detected with linezolid during the study. Conclusions: The absence of significant deviations regarding indications and dosage regimen of linezolid is shown. A possible informative intervention regarding the sequential therapy of this antibiotic is objectified, improving its use and patient safety.

Erreferentzia bibliografikoak

  • 1. Agencia Española de Medicamentos y Productos Sanitarios. Madrid. Centro de Información on line de Medicamentos de la AEMPS. Ficha técnica de linezolid 2mg/ml solución para perfusión EFG. Consultado el de 30 noviembre de 2020. Disponible en: https://cima.aemps.es/cima/dochtml/ft/80027/ FT_80027.html#4-1-indicaciones-terap-uticas
  • 2. Goodman L, Bunton L, Hilal-Dandan R, Knollmann B, Gilman A, Gilman A et al. Las bases farmacológicas de la terapéutica.: McGraw-Hill; 2019.
  • 3. Blanquer J, Aspa J, Anzueto A, Ferrer M, Gallego M, Rajas O et al. Normativa SEPAR: Neumonía nosocomial. Arch Bronconeumol. 2011; 47(10):510–520.
  • 4. Suárez L, Gamonal L, Gómez R, Romay E, Pedrosa C, García B. Guía clínica de Celulitis. Consultado el 30 de noviembre de 2020. Disponible en: https://www.fisterra.com/guias-clinicas/celulitis/
  • 5. Mensa J, Barberán J, Llinares P, Picazo J, Bouza E, Álvarez F et al. Guía de tratamiento de la infección producida por Staphylococcus aureus resistente a meticilina. Rev Esp Quimioter 2008; 21(4):234-258.
  • 6. Kateete D, Moses E, Kigozi E, Kisukye J, Hannington B, Nobert F et al. Species, antibiotic susceptibility profiles and van gene frequencies among enterococci isolated from patients at Mulago National Referral Hospital in Kampala, Uganda BMC Infectious Diseases ;2019.9;486.
  • 7. Pérez- Cebrián M, Morales M, Font-Noguera I, Monte-Boquet E, Poveda J, Martín J et al. Study on the Linezolid Prescription According to the Approval of Indication in a University Hospital.Iran J Pharm Res. 2015; 14(3): 857–864.
  • 8. Von Spreckelsen, N, Jung N, Telentschak S, Hampl J, Goldbrunner R, Grau S. Current treatment concepts for iatrogenic ventriculitis: a nationwide survey in Germany. Acta Neurochir. 2018; 160(3): 505-508.
  • 9. Safa L, Afif N, Hajjej Z. Proper use of antibiotics: situation of linezolid at the intensive care unit of the Tunisian Military Hospital. Pan Afr Med J. 2016; 25: 196.
  • 10. Cocker D, Ryan H, Sloan D, Singh B. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev. 2019; 2019(3).
  • 11. Al-Anazi K, Al-Jasser A, Alsaleh K. Infections Caused by Mycobacterium tuberculosis in Recipients of Hematopoietic Stem Cell Transplantation. Front. Oncol., 26 August 2014. Consultado el 10 de dicembre de 2020. Disponible en: https://doi.org/10.3389/fonc.2014.00231
  • 12. Agencia Española de Medicamentos y Productos Sanitarios. Madrid. Centro de Información on line de Medicamentos de la AEMPS Ficha técnica de Vancomicina Accord 1gr IV. Consultado el 19 de noviembre 2020. Disponible en: https://cima.aemps.es/cima/pdfs/es/ft/62292/P_62292.pdf
  • 13. Fernández L, Pérez P, Martín C. Estudio de Utilización de linezolid y daptomicina. Rev. OFIL 2016, 26;2: 127-130.
  • 14. Rivas R, Barrera M, González L, Dominguez V. Sánchez R, Romero M. Efectividad y uso del linezolid en planta de hospitalización. Farm Hosp. 2011; 35(6):322-325.
  • 15. Prats M. Linezolid: estudio de utilización, farmacocinética, efectividad y seguridad. (Doctorado). Universidad Complutense de Madrid. (2017).
  • 16. Sociedad Española de Medicina Peventiva Salud Pública e Higiene. Estudio de Prevalencia de las Enfermedades Nosocomiales en España. 2019. Consultado el 12 de diciembre de 2020. Disponible en: https://epine.es/api/documento-publico/2019%20EPINE%20Informe%20Espa%C3%B1a%2027112019. pdf/reports-esp
  • 17. Zyvox (linezolid) inyection label . 2011 Consultado el 30 de noviembre de 2020.Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2012/021132s027lbl.pdf
  • 18. Pontefract B, Madaras-Kelly K. Linezolid for Treatment of Urinary Tract Infections Caused by Vancomycin-resistant Enterococci. Open Forum Infectious Diseases. 2019;6(2):S537-S537.
Datuen iturria: Dialnet